Nature Medicine
February 16, 2026
David Erritzøe, Tommaso Barba, Tiffanie Benway et al.
4 citations
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled,...
Ganaya
February 14, 2026
Tinon Citraning Harisuci, Vikri Islah Khafidz, Faricha Annisa et al.
Individuals with mental disabilities are vulnerable to anxiety, stress, and depression that affect emotional and social functioning. This study aimed to evaluate the effect of Dance Movement Therapy (DMT) accompanied by Osho Kundalini music on reducing symptoms of anxiety, stress, and depression. The study employed a pre-experimental one-group pretest–posttest design involving 15 participants...
Pharmaceuticals
February 14, 2026
Petra Dolenec, Goran Pelčić, Kristina Pilipović et al.
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve complex vascular, metabolic, and inflammatory mechanisms. Retinal ganglion cells are particularly vulnerable to ischemia-reperfusion injury, oxidative stress, and chronic neuroinflammation, leading to progressive disconnection from central visual...
Zenodo (CERN European Organization for Nuclear Research)
February 8, 2026
Eugene Catrambone
preprint
When Time Stops: Inside the Mind’s Clock is a theoretical preprint monograph exploring how subjective time perception may relate to brain dynamics, informational complexity, and cytoskeletal processes. The work introduces the Scalar Clock Model, in which subjective duration is represented by a scalar variable (φ) whose accumulation rate may be influenced by large-scale neural activity and...
Pharmacopsychiatry
February 5, 2026
Tianyi Xu, Sabrina Wong, Gia Han Le et al.
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist activity at the 5-hydroxytryptamine 2B receptor, a signalling pathway known to mechanistically mediate drug-induced valvular heart disease. This systematic review evaluates whether chronic or repeated use of psychedelics and...
Journal of Psychopharmacology
February 5, 2026
Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...
Research Square
February 2, 2026
Ziv Ben-Zion, Guy Simon, Teddy Lazebnik
preprint
Abstract Large language models (LLMs) are increasingly consulted by individuals for support during psychedelic experiences ("trip sitting"), yet no framework exists to evaluate whether these models can accurately simulate or safely respond to altered states of consciousness. We aimed to determine if LLMs can be induced to generate narratives resembling human psychedelic experiences and to...
European Neuropsychopharmacology
February 1, 2026
Isabel Werle, Francisco S Guimarães, Rafael G. Dos Santos et al.
Rodent studies have shown that psychedelic drugs can enhance fear extinction. However, investigations to date have relied on normative aversive conditioning procedures, which limit their relevance to trauma-related memories, as these tend to be overgeneralized and resistant to extinction. Fear extinction depends on activity and plasticity within the infralimbic (IL) region of the medial...
February 1, 2026
Carlton J Spotswood
Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998....
Biological Psychiatry
February 1, 2026
Jin Zhang, Cong Lin, Xinyou Lv et al.
1 citation
Classic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), have emerged as potent modulators of neuroplasticity and metaplasticity in the adult brain, offering novel therapeutic strategies for neuropsychiatric disorders. Recent findings reveal that beyond their transient psychotropic effects, these compounds activate serotonin 5-HT2A receptors...